...
机译:耐霉菌和复发复发急性淋巴细胞白血病(ALL)治疗的预后因素(IO),CD22单克隆抗体治疗
Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;
Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;
Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;
Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;
Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;
Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;
Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;
Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;
Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;
Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;
Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;
机译:耐霉菌和复发复发急性淋巴细胞白血病(ALL)治疗的预后因素(IO),CD22单克隆抗体治疗
机译:CD22单克隆抗体inotuzumab ozogamicin在难治性和复发性急性淋巴细胞白血病中的结果
机译:Inotuzumab ozogamicin对法国小儿患者的富有复发或难损CD22 CD22-阳性B细胞急性淋巴细胞白血病
机译:干涉法检测上皮性卵巢癌的早期标志物和急性淋巴细胞白血病的预后标志物
机译:根据2017年日本成人白血病研究组(JALSG)AML201研究治疗的成人急性髓性白血病患者的遗传学预测,根据2017 ELN风险分层进行预后分析
机译:CD22单克隆抗体Inotuzumab Ozogamicin治疗难治性和复发性急性淋巴细胞白血病患者的预后因素
机译:Inotuzumab ozogamicin用于在Ino-Vate试验中复发/难治性急性淋巴细胞白血病:CD22药效学,疗效和基线CD22的安全性